Recombinant DNA Technology — Current Affairs 2026

Current Affairs Connections

Recent developments and news linked to Recombinant DNA Technology.

GEAC Grants Environmental Clearance for GM Mustard DMH-11, but Supreme Court Stay Continues

October 2022 (Clearance), Ongoing (SC Stay)

In October 2022, the Genetic Engineering Appraisal Committee (GEAC), India's apex biotech regulator, granted environmental clearance for the commercial cultivation of Genetically Modified (GM) mustard hybrid DMH-11. This marked a significant milestone as it was the first GM food crop to receive such approval in India. However, the Supreme Court of India subsequently imposed a stay on its commercial release, responding to Public Interest Litigations (PILs) raising concerns about biosafety, environmental impact, and the adequacy of regulatory oversight. The court has sought further data and clarifications from the government, indicating the continued judicial scrutiny and public apprehension surrounding GM food crops in India. The debate highlights the complex interplay between scientific consensus, regulatory processes, and societal concerns.

UPSC Angle: This is a critical and recurring topic for UPSC, especially for GS Paper III (Agriculture, Environment, Science & Technology). Aspirants must understand the scientific rationale behind GM mustard (e.g., barnase/barstar system for hybrid vigor), the GEAC's role, the 'precautionary principle' invoked by activists, and the Supreme Court's intervention. Analyze the arguments for and against GM crops in the Indian context, considering food security, farmer livelihoods, biodiversity, and ethical dimensions. [VY:SCI-07-06]

Background (2024)

Earlier events that provide context for this topic.

India's Push for Indigenous Biotech Solutions: Focus on Biologics and Diagnostics

March 2024

The Indian government, through the Department of Biotechnology (DBT) and NITI Aayog, has intensified its focus on fostering indigenous development and manufacturing of biologics (like recombinant proteins, monoclonal antibodies, and vaccines) and advanced diagnostic kits. This push is driven by lessons from the COVID-19 pandemic, highlighting the need for self-reliance in healthcare technologies. Recent policy discussions emphasize streamlining regulatory approvals for novel rDNA-derived products, increasing funding for biotech startups, and establishing advanced biomanufacturing hubs. This initiative aims to position India as a global leader in affordable and accessible biotech products, leveraging its strong scientific talent pool and existing pharmaceutical infrastructure. The focus is on both therapeutic and prophylactic applications, ensuring health security and economic growth.

UPSC Angle: This reflects India's strategic shift towards 'Atmanirbhar Bharat' in biotechnology. UPSC aspirants should analyze the policy mechanisms, funding allocations, and regulatory reforms being implemented to achieve this goal. Discuss the potential impact on public health, pharmaceutical exports, and job creation. Connect it to India's broader science and technology policy and its implications for innovation and global competitiveness.